Compare CNTB & VECA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CNTB | VECA |
|---|---|---|
| Founded | 2012 | N/A |
| Country | United States | |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 135.7M | 131.3M |
| IPO Year | 2020 | 2025 |
| Metric | CNTB | VECA |
|---|---|---|
| Price | $2.33 | $10.00 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $8.67 | N/A |
| AVG Volume (30 Days) | ★ 328.4K | 25.3K |
| Earning Date | 08-13-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $64,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.23 | $9.87 |
| 52 Week High | $3.82 | $10.05 |
| Indicator | CNTB | VECA |
|---|---|---|
| Relative Strength Index (RSI) | 52.83 | 53.77 |
| Support Level | $2.30 | $9.90 |
| Resistance Level | $2.69 | N/A |
| Average True Range (ATR) | 0.16 | 0.04 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 57.30 | 72.22 |
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.
Vernal Capital Acquisition Corp is a blank check company.